Galectin Therapeutics (GALT) 10-K2007 FY Annual report

Filed: 28 Mar 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: anthony, arena, attestation, Australia, biochemist, book, Brazil, Brigham, Canada, China, colin, collagen, conserve, copyright, declaratory, delisted, enrichment, estate, gathered, housing, Japan, left, median, mitigate, neill, newly, nonfinancial, nonrecurring, nonrefundable, promulgated, readily, reclassification, regain, reorganization, robust, runway, safe, salary, split, squeglia, statute, Street, Summer, tabular, taught, taxation, temporary, theodore, tradable, unissued, unjust, Unregistered, voluntarily, zucconi

Removed: accelerate, acceleration, accessible, acting, active, add, Administrator, ADVANCING, Agriculture, anatomy, anemia, Ann, answer, answered, arbitration, arbitrator, author, avastin, Aviv, Barbara, bevacizumab, Binder, biochemistry, biology, BioSignature, blood, carl, Carolina, center, certified, Charm, cisplatin, College, colon, commonly, compound, concert, conditioned, Connecticut, Conventional, Councilor, creating, Czirr, damage, delaying, delivered, demand, Dendreon, Department, deputy, designated, deterring, developmental, digestive, direction, diseased, disrupting, division, doxorubicin, edited, editor, eliminate, elimination, engineering, enhanced, Equine, erosion, expedite, exposure, facilitate, fast, fatigue, fax, fellow, field, foresee, formation, Foundation, founder, founding, fundamental, gastrointestinal, GlycoFi, GLYCOSCIENCE, goal, hair, Hebrew, honorary, Immunogen, immunology, immunotherapy, improving, indemnify, industrial, Institute, international, internationally, irinotecan, iv, Jefferson, Jerusalem, Johnson, kill, knowledge, leading, leave, leucovorin, listed, LLC, localized, maintenance, manager, Mary, McNeil, merged, Michigan, microbiology, minimize, Momenta, move, national, nausea, negatively, North, oncology, opposition, optimal, Optimer, optimize, organ, organized, oxaliplatin, parasitology, partially, participated, pathology, permitting, person, portfolio, potentially, predecessor, preferable, preserve, preventing, preventive, recapitalization, Region, regional, register, Rehovot, reimbursable, release, replication, reproductive, responded, River, SafeScience, Science, Seattle, seeking, senior, served, short, Society, Southern, strong, supplemental, Surveillance, surviving, targeting, Tel, telephone, Teratology, terminable, terminate, terminated, termination, thereof, thirtieth, thirty, toxic, Toxicological, track, tract, training, transdermal, treating, Treaty, Tuskegee, ulceration, unanticipated, unaudited, undelivered, undertook, University, unmet, Vaccine, veterinary, Virginia, Weizmann, West, William, work, world, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GALT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Pro-Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Platt, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



March 28, 2008	/s/ David Platt
	Name:	David Platt
	Title:	Chief Executive Officer (principal executive officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pro-Pharmaceuticals, Inc. and will be retained by Pro-Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.